Melanoma — Trials · CancerIndex

Clinical trials

Registered studies

3,221 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 605
Recruiting: 316
Ph III recruiting: 30
Growth YoY: +37.2%
Industry share: 33%
Top sponsor: M.D. Anderson Cancer Center
Termination share: 37.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (571)

clinicaltrialsPublishedShowing 1,151–1,200 of 1,379 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT00436605	Dasatinib in Treating Patients With Stage III Melanoma That Cannot Be Removed By Surgery or Stage IV Melanoma	completed	Phase 2	39	National Cancer Institute (NCI)NIH	1	May 15, 2014	clinicaltrials
NCT01166126	Temsirolimus/AZD 6244 for Treatment-naive With BRAF Mutant Unresectable Stage IV	terminated	Phase 2	4	National Cancer Institute (NCI)NIH	1	May 15, 2014	clinicaltrials